You are not logged in.
Openly accessible

Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools

Bousman, Chad A, Forbes, Malcolm, Jayaram, Mahesh, Eyre, Harris, Reynolds, Charles F, Berk, Michael, Hopwood, Malcolm and Ng, Chee 2017, Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools, BMC psychiatry, vol. 17, pp. 1-7, doi: 10.1186/s12888-017-1230-5.

Attached Files
Name Description MIMEType Size Downloads
eyre-antidepressantprescribing-2017-1.pdf Published version application/pdf 884.24KB 0

Title Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools
Author(s) Bousman, Chad A
Forbes, Malcolm
Jayaram, Mahesh
Eyre, Harris
Reynolds, Charles F
Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Hopwood, Malcolm
Ng, Chee
Journal name BMC psychiatry
Volume number 17
Article ID 60
Start page 1
End page 7
Total pages 7
Publisher BioMed Central
Place of publication London, Eng.
Publication date 2017
ISSN 1471-244X
1471-244X
Keyword(s) decision support
major depressive disorder
pharmacogenomics
precision medicine
psychiatry
science & technology
life sciences & biomedicine
consortium CPIC guideline
implementation consortium
psychotropic medications
resource utilization
CYP2C19 genotypes
health
care
personalization
Summary About half of people who take antidepressants do not respond and many experience adverse effects. These detrimental outcomes are in part a result of the impact of an individual's genetic profile on pharmacokinetics and pharmcodynamics. If known and made available to clinicians, this could improve decision-making and antidepressant therapy outcomes. This has spurred the development of numerous pharmacogenetic-based decision support tools. In this article, we provide an overview of pharmacogenetic decision support tools, with particular focus on tools relevant to antidepressants. We briefly describe the evolution and current state of antidepressant pharmacogenetic decision support tools in clinical practice, followed by the evidence-base for their use. Finally, we present a series of considerations for clinicians contemplating use of these tools and discuss the future of antidepressant pharmacogenetic decision support tools.
Language eng
DOI 10.1186/s12888-017-1230-5
Field of Research 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
1103 Clinical Sciences
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2017, The Authors
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30091351

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in TR Web of Science
Scopus Citation Count Cited 1 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 9 Abstract Views, 5 File Downloads  -  Detailed Statistics
Created: Thu, 16 Feb 2017, 13:58:02 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.